+

PE20181921A1 - NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS - Google Patents

NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS

Info

Publication number
PE20181921A1
PE20181921A1 PE2018001974A PE2018001974A PE20181921A1 PE 20181921 A1 PE20181921 A1 PE 20181921A1 PE 2018001974 A PE2018001974 A PE 2018001974A PE 2018001974 A PE2018001974 A PE 2018001974A PE 20181921 A1 PE20181921 A1 PE 20181921A1
Authority
PE
Peru
Prior art keywords
seq
new anti
sirpa
antibodies
therapeutic applications
Prior art date
Application number
PE2018001974A
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Vanessa Gauttier
Virginie Thepenier
Sabrina Pengam
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of PE20181921A1 publication Critical patent/PE20181921A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/80Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a nuevos anticuerpos anti-SIRPa o un fragmento de union a antigeno del mismo que comprende: a) un dominio variable de cadena pesada que comprende HCDR1, HCDR2 y HCDR3 en la secuencia de aminoacidos SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 17 respectivamente y b) un dominio variable de cadena ligera que comprende LCDR1, LCDR2 y LCDR3 en la secuencia de aminoacidos SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 capaces de antagonizar especificamente la interaccion entre SIRPa y CD47, sin afectar la interaccion entre SIRPg Y CD47. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos anticuerpos son utiles en el tratamiento del cancer inflamatorio, cancer con celulas mieloides infiltradas, entre otros.
PE2018001974A 2016-04-14 2017-04-14 NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS PE20181921A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
EP17305182 2017-02-17

Publications (1)

Publication Number Publication Date
PE20181921A1 true PE20181921A1 (es) 2018-12-11

Family

ID=58185461

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001974A PE20181921A1 (es) 2016-04-14 2017-04-14 NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS

Country Status (11)

Country Link
EP (1) EP3443010B1 (es)
CN (1) CN109071664B (es)
AU (1) AU2017248626B2 (es)
BR (1) BR112018070823A2 (es)
CA (1) CA3020373A1 (es)
CO (1) CO2018010855A2 (es)
EA (1) EA201891882A1 (es)
PE (1) PE20181921A1 (es)
PT (1) PT3443010T (es)
SG (1) SG11201808465UA (es)
WO (1) WO2017178653A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
SMT202400438T1 (it) 2016-04-14 2024-11-15 Ose Immunotherapeutics Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CA3051318A1 (en) * 2017-02-17 2018-08-23 Ose Immunotherapeutics New uses of anti-sirpg antibodies
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
ES2981193T3 (es) * 2017-05-16 2024-10-07 Byondis Bv Anticuerpos antisirpalpha
SG11202000053TA (en) 2017-08-02 2020-02-27 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
EP3694881A1 (en) * 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
WO2019080883A1 (en) * 2017-10-26 2019-05-02 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF
WO2019175218A1 (en) * 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
CN112566642B (zh) 2018-03-14 2025-01-17 纪念斯隆凯特琳癌症中心 抗聚唾液酸抗体及其用途
CN112040979A (zh) * 2018-03-21 2020-12-04 Alx肿瘤生物技术公司 针对信号调控蛋白α的抗体和使用方法
PE20210342A1 (es) 2018-05-25 2021-02-23 Alector Llc Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
CN117024593A (zh) 2018-07-10 2023-11-10 国立大学法人神户大学 抗SIRPα抗体
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
EP3856787A4 (en) * 2018-09-27 2022-06-29 Celgene Corporation SIRPalpha BINDING PROTEINS AND METHODS OF USE THEREOF
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020091596A1 (en) 2018-10-29 2020-05-07 Umc Utrecht Holding B.V. Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
AU2019380503A1 (en) * 2018-11-14 2021-06-03 Arch Oncology, Inc. Therapeutic SIRPα antibodies
SG11202104431PA (en) * 2018-11-15 2021-05-28 Byondis Bv HUMANIZED ANTI-SIRPα ANTIBODIES
AU2019409805A1 (en) * 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
US20220143210A1 (en) * 2019-02-27 2022-05-12 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatement of malignancies
US20220235144A1 (en) * 2019-03-04 2022-07-28 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
EP3756688A1 (en) 2019-06-25 2020-12-30 Université de Nantes Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
US20220401516A1 (en) 2020-06-01 2022-12-22 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
US20230414778A1 (en) 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
JP7663265B2 (ja) 2020-11-30 2025-04-16 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗SIRPα抗体またはその抗原結合断片および適用
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
MX2023013259A (es) 2021-05-13 2023-11-27 Alx Oncology Inc Terapias de combinacion para el tratamiento del cancer.
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用FLT3L—Fc融合蛋白之方法
WO2022247933A1 (zh) * 2021-05-28 2022-12-01 百奥泰生物制药股份有限公司 抗SIPRα抗体及其应用
KR20240027677A (ko) 2021-06-04 2024-03-04 베링거 인겔하임 인터내셔날 게엠베하 항-sirp-알파 항체
JP2024520593A (ja) 2021-06-23 2024-05-24 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリエルコール(diacylglyercol)キナーゼ調節化合物
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
EP4389767A1 (en) 2021-08-17 2024-06-26 Hangzhou Jiuyuan Gene Engineering Co., Ltd Monoclonal antibody targeting sirp? and use thereof
TWI857377B (zh) 2021-10-28 2024-10-01 美商基利科學股份有限公司 嗒-3(2h)-酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
CN118679183A (zh) 2021-11-29 2024-09-20 Ose免疫疗法公司 特异性拮抗剂抗sirpg抗体
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4464703A3 (en) 2022-03-17 2025-02-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN119031937A (zh) 2022-03-24 2024-11-26 吉利德科学公司 用于治疗表达Trop-2的癌症的联合疗法
CN119013041A (zh) 2022-04-05 2024-11-22 吉利德科学公司 用于治疗结肠直肠癌的抗体疗法的组合
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
TW202408584A (zh) 2022-05-10 2024-03-01 日商第一三共股份有限公司 抗體-藥物結合物與抗SIRPα抗體之組合
CN119497722A (zh) 2022-06-01 2025-02-21 Alx肿瘤生物技术公司 用于治疗尿路上皮癌的组合疗法
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US20100239578A1 (en) * 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CN101780283A (zh) * 2010-03-16 2010-07-21 中国人民解放军第二军医大学 信号调节蛋白α在制备预防和治疗肿瘤的DC疫苗中的应用
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体

Also Published As

Publication number Publication date
PT3443010T (pt) 2024-10-21
CN109071664B (zh) 2023-02-21
WO2017178653A2 (en) 2017-10-19
AU2017248626B2 (en) 2024-05-09
CN109071664A (zh) 2018-12-21
EP3443010A2 (en) 2019-02-20
CA3020373A1 (en) 2017-10-19
EP3443010B1 (en) 2024-08-07
WO2017178653A3 (en) 2018-07-05
EA201891882A1 (ru) 2019-07-31
SG11201808465UA (en) 2018-10-30
AU2017248626A1 (en) 2018-10-11
CO2018010855A2 (es) 2018-11-13
BR112018070823A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141151A1 (es) Proteinas de union al antigeno cd27l
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
PE20190630A1 (es) Anticuerpos de anti-tim-3
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载